Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more
Coloplast A/S (CLPBF) - Net Assets
Latest net assets as of December 2025: $13.80 Billion USD
Based on the latest financial reports, Coloplast A/S (CLPBF) has net assets worth $13.80 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($48.80 Billion) and total liabilities ($34.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.80 Billion |
| % of Total Assets | 28.29% |
| Annual Growth Rate | 10.65% |
| 5-Year Change | 97.0% |
| 10-Year Change | 217.5% |
| Growth Volatility | 24.87 |
Coloplast A/S - Net Assets Trend (2002–2025)
This chart illustrates how Coloplast A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Coloplast A/S (2002–2025)
The table below shows the annual net assets of Coloplast A/S from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $16.09 Billion | -10.32% |
| 2024-09-30 | $17.94 Billion | +3.72% |
| 2023-09-30 | $17.30 Billion | +108.62% |
| 2022-09-30 | $8.29 Billion | +1.52% |
| 2021-09-30 | $8.17 Billion | +10.29% |
| 2020-09-30 | $7.41 Billion | +7.13% |
| 2019-09-30 | $6.91 Billion | +7.71% |
| 2018-09-30 | $6.42 Billion | +7.83% |
| 2017-09-30 | $5.95 Billion | +17.44% |
| 2016-09-30 | $5.07 Billion | +7.69% |
| 2015-09-30 | $4.71 Billion | -25.10% |
| 2014-09-30 | $6.28 Billion | -7.18% |
| 2013-09-30 | $6.77 Billion | +12.03% |
| 2012-09-30 | $6.04 Billion | +34.93% |
| 2011-09-30 | $4.48 Billion | +29.72% |
| 2010-09-30 | $3.45 Billion | +21.12% |
| 2009-09-30 | $2.85 Billion | +24.40% |
| 2008-09-30 | $2.29 Billion | -4.54% |
| 2007-09-30 | $2.40 Billion | -14.44% |
| 2006-09-30 | $2.81 Billion | +11.58% |
| 2005-09-30 | $2.51 Billion | +6.24% |
| 2004-09-30 | $2.37 Billion | +17.73% |
| 2003-09-30 | $2.01 Billion | +28.11% |
| 2002-09-30 | $1.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coloplast A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1344.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $17.64 Billion | 109.63% |
| Common Stock | $227.57 Million | 1.41% |
| Other Comprehensive Income | $-1.78 Billion | -11.05% |
| Other Components | $434.00K | 0.00% |
| Total Equity | $16.09 Billion | 100.00% |
Coloplast A/S Competitors by Market Cap
The table below lists competitors of Coloplast A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
East West Bancorp Inc
NASDAQ:EWBC
|
$14.29 Billion |
|
Wal Mart de Mexico SAB de CV
PINK:WMMVF
|
$14.31 Billion |
|
GUOTAI JUNAN SEC. H YC1
F:153A
|
$14.32 Billion |
|
CLP Holdings Ltd
PINK:CLPHY
|
$14.34 Billion |
|
Techtronic Industries Company Limited
PINK:TTNDF
|
$14.25 Billion |
|
Genuine Parts Co
NYSE:GPC
|
$14.24 Billion |
|
James Hardie Industries plc
PINK:JHIUF
|
$14.21 Billion |
|
IDEX Corporation
NYSE:IEX
|
$14.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coloplast A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,942,000,000 to 16,091,000,000, a change of -1,851,000,000 (-10.3%).
- Net income of 3,629,000,000 contributed positively to equity growth.
- Dividend payments of 4,949,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 270,000,000.
- Other factors decreased equity by 261,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.63 Billion | +22.55% |
| Dividends Paid | $4.95 Billion | -30.76% |
| Other Comprehensive Income | $-270.00 Million | -1.68% |
| Other Changes | $-261.00 Million | -1.62% |
| Total Change | $- | -10.32% |
Book Value vs Market Value Analysis
This analysis compares Coloplast A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.98x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-09-30 | $6.65 | $99.57 | x |
| 2003-09-30 | $8.49 | $99.57 | x |
| 2004-09-30 | $10.05 | $99.57 | x |
| 2005-09-30 | $10.74 | $99.57 | x |
| 2006-09-30 | $11.87 | $99.57 | x |
| 2007-09-30 | $10.52 | $99.57 | x |
| 2008-09-30 | $10.50 | $99.57 | x |
| 2009-09-30 | $13.38 | $99.57 | x |
| 2010-09-30 | $16.21 | $99.57 | x |
| 2011-09-30 | $21.32 | $99.57 | x |
| 2012-09-30 | $28.36 | $99.57 | x |
| 2013-09-30 | $31.46 | $99.57 | x |
| 2014-09-30 | $29.44 | $99.57 | x |
| 2015-09-30 | $22.10 | $99.57 | x |
| 2016-09-30 | $23.85 | $99.57 | x |
| 2017-09-30 | $28.01 | $99.57 | x |
| 2018-09-30 | $30.22 | $99.57 | x |
| 2019-09-30 | $32.44 | $99.57 | x |
| 2020-09-30 | $34.72 | $99.57 | x |
| 2021-09-30 | $38.31 | $99.57 | x |
| 2022-09-30 | $38.97 | $99.57 | x |
| 2023-09-30 | $80.27 | $99.57 | x |
| 2024-09-30 | $79.78 | $99.57 | x |
| 2025-09-30 | $71.40 | $99.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coloplast A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.55%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.04%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 3.00x
- Recent ROE (22.55%) is below the historical average (39.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 49.17% | 13.66% | 1.25x | 2.87x | $611.80 Million |
| 2003 | 28.11% | 9.90% | 1.06x | 2.69x | $361.40 Million |
| 2004 | 25.00% | 9.68% | 1.08x | 2.40x | $352.73 Million |
| 2005 | 22.01% | 8.87% | 1.05x | 2.35x | $301.80 Million |
| 2006 | 21.90% | 9.15% | 0.84x | 2.85x | $333.60 Million |
| 2007 | 34.90% | 10.41% | 1.04x | 3.23x | $597.20 Million |
| 2008 | 31.24% | 8.45% | 1.06x | 3.49x | $486.10 Million |
| 2009 | 30.98% | 10.01% | 1.11x | 2.79x | $598.00 Million |
| 2010 | 36.01% | 13.03% | 1.23x | 2.25x | $897.80 Million |
| 2011 | 40.62% | 17.88% | 1.10x | 2.06x | $1.37 Billion |
| 2012 | 36.31% | 19.90% | 1.08x | 1.68x | $1.59 Billion |
| 2013 | 40.05% | 23.30% | 1.24x | 1.38x | $2.03 Billion |
| 2014 | 38.04% | 19.23% | 1.20x | 1.65x | $1.76 Billion |
| 2015 | 19.10% | 6.46% | 1.29x | 2.30x | $428.40 Million |
| 2016 | 62.02% | 21.41% | 1.33x | 2.17x | $2.64 Billion |
| 2017 | 63.79% | 24.45% | 1.29x | 2.02x | $3.20 Billion |
| 2018 | 59.91% | 23.38% | 1.40x | 1.83x | $3.20 Billion |
| 2019 | 56.02% | 21.59% | 1.41x | 1.84x | $3.18 Billion |
| 2020 | 56.67% | 22.63% | 1.37x | 1.82x | $3.46 Billion |
| 2021 | 59.07% | 24.84% | 1.23x | 1.94x | $4.01 Billion |
| 2022 | 56.75% | 20.84% | 0.65x | 4.22x | $3.88 Billion |
| 2023 | 27.65% | 19.52% | 0.51x | 2.78x | $3.05 Billion |
| 2024 | 28.16% | 18.69% | 0.56x | 2.68x | $3.26 Billion |
| 2025 | 22.55% | 13.04% | 0.58x | 3.00x | $2.02 Billion |
Industry Comparison
This section compares Coloplast A/S's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coloplast A/S (CLPBF) | $13.80 Billion | 49.17% | 2.53x | $14.28 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |